Results 101 to 110 of about 101,032 (306)
Journal of Magnesium and Alloys, 2018 In the present study, the influence of dynamic process parameters such as water pressure, traverse speed and abrasive mass flow rate on depth of penetration and surface topography in high strength AZ91 magnesium alloy were investigated using Abrasive ...
C A Niranjan, S Srinivas, M Ramachandra
doaj +1 more source
PSYNDEX Tests Review für BMS - VERFAHREN ZUR SKALIERTEN ERFASSUNG ERLEBTER BEANSPRUCHUNGSFOLGEN
, 1982 This is a PSYNDEX Tests Review of BMS - VERFAHREN ZUR SKALIERTEN ERFASSUNG ERLEBTER BEANSPRUCHUNGSFOLGEN. PSYNDEX Tests Reviews are written in German and describe and evaluate psychological and educational tests used in the German-speaking countries ...
Richter, Peter, Plath, Hans-Eberhard
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source
Cracking the Code: Genotype–Phenotype Correlation Models in Sarcoglycanopathies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Sarcoglycanopathies are among the most severe limb‐girdle muscular dystrophies (LGMD), though milder presentations have been described. These diseases are primarily caused by missense variants, but the limited predictability of their effect on protein maturation, complex formation, and transport has hindered reliable genotype ...
Leonela Luce +72 more
wiley +1 more source
A microscopic analogue of the BMS group
, 2023 We consider a microscopic analogue of the BMS analysis of asymptotic symmetries by analysing universal geometric structures on infinitesimal tangent light cones.
Daniel Alexander Weiss
core +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane +19 more
wiley +1 more source
, 2002 BMS 284756 penetrated well into inflamed meninges (44% +/- 11%) and produced good bactericidal activity (-0.82 +/- 0.22 Delta log(10) CFU/ml. h) in the treatment of experimental meningitis in rabbits due to a penicillin-sensitive strain.
Cottagnoud, M +4 more
core +1 more source
The Bi-Functional Organization of Human Basement Membranes [PDF]
, 2013 The current basement membrane (BM) model proposes a single-layered extracellular matrix (ECM) sheet that is predominantly composed of laminins, collagen IVs and proteoglycans.
Paul Bernhard Henrich (430036) +40 more
core +1 more source